Jupiter Topco LLC Purchases New Position in Quest Diagnostics Incorporated $DGX

Key Points

• Jupiter Topco LLC acquired 10,393 Quest Diagnostics shares in the second quarter, valued at approximately $2.2 million. Institutional investors own 88.06% of DGX.
• Quest Diagnostics reported quarterly EPS of $3.12, beating estimates by $0.30, while revenue rose 10.2% year over year to $3.04 billion. The company issued fiscal 2026 EPS guidance of $11.05–$11.25.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $235.31; the company also declared a quarterly dividend of $0.86 per share, yielding approximately 1.4% annually.

Jupiter Topco LLC purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 10,393 shares of the medical research company's stock, valued at approximately $2,201,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DGX. Moneta Group Investment Advisors LLC lifted its holdings in shares of Quest Diagnostics by 3.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company's stock valued at $241,000 after purchasing an additional 50 shares in the last quarter. Ossiam grew its holdings in Quest Diagnostics by 6.1% during the third quarter. Ossiam now owns 1,059 shares of the medical research company's stock worth $202,000 after buying an additional 61 shares in the last quarter. Independent Advisor Alliance raised its position in Quest Diagnostics by 1.6% in the 4th quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company's stock valued at $746,000 after buying an additional 66 shares during the last quarter. Brown Advisory Inc. raised its position in Quest Diagnostics by 1.0% in the 4th quarter. Brown Advisory Inc. now owns 7,287 shares of the medical research company's stock valued at $1,265,000 after buying an additional 71 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Quest Diagnostics by 9.6% during the 4th quarter. Hantz Financial Services Inc. now owns 835 shares of the medical research company's stock valued at $145,000 after acquiring an additional 73 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, SVP Mark E. Delaney sold 1,600 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the transaction, the senior vice president directly owned 10,335 shares of the company's stock, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the transaction, the chief executive officer directly owned 122,423 shares of the company's stock, valued at $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 34,277 shares of company stock worth $8,316,493. Insiders own 0.88% of the company's stock.

Wall Street Analysts Forecast Growth

DGX has been the topic of a number of analyst reports. Jefferies Financial Group reaffirmed a "buy" rating and set a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday, July 23rd. Weiss Ratings upgraded shares of Quest Diagnostics from a "buy (b+)" rating to a "buy (a-)" rating in a report on Wednesday, August 12th. Argus set a $260.00 price target on shares of Quest Diagnostics in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a "neutral" rating in a report on Tuesday, July 28th. Finally, UBS Group upped their price objective on shares of Quest Diagnostics from $220.00 to $232.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $235.31.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $239.60 on Friday. The business's fifty day simple moving average is $227.10 and its 200 day simple moving average is $208.11. The firm has a market capitalization of $26.44 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 2.20 and a beta of 0.55. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $247.19. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio (DPR) is 36.52%.

Quest Diagnostics Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.